Symbols

SILO

Silo Pharma·NASDAQ

--(--)

SILO Profile

Silo Pharma, Inc.

A developmental stage biopharmaceutical company that developing products for indications such as PTSD and Alzheimer's disease

Industry

Pharmaceutical

Established Date

07/13/2010

Listing Date

09/27/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.silopharma.com

Security Type

Common stock

Office address

677 N. Washington Boulevard, Sarasota, FL 34236

Business

Introduction

Silo Pharma, Inc., was incorporated in New York State on July 13, 2010. On January 24, 2013, the Company changed its domicile from New York to Delaware. On December 19, 2023, the company changed its state of incorporation from Delaware to Nevada. The company is a development-stage biopharmaceutical and cryptocurrency company focused on developing novel therapies for unmet needs such as post-traumatic stress disorder, stress anxiety disorder, fibromyalgia and central nervous system diseases. Its main program, SPC-15, is an intranasal drug candidate for the treatment of post-traumatic stress disorder and stress anxiety disorder.